Cellectis (CLLS) Says Two Issued US Patents Granted for CRISPR Use in T-Cells – StreetInsider.com
Channel NewsAsia |
Cellectis (CLLS) Says Two Issued US Patents Granted for CRISPR Use in T-Cells
StreetInsider.com Cellectis (NASDAQ: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the issuance of two U.S. patents – US 9,855,297 and US 9,890,393 – for the … France’s Cellectis wins US patents for gene editing technologyETHealthworld.com |
|
DowDuPont revealed as the surprise leader in global CRISPR patents; study points to potential trouble ahead
IAM (blog) A new study of the global CRISPR patent landscape released today provides the most detailed insight yet into how entities are seeking to protect their inventions relating to the revolutionary technology. Speaking exclusively to IAM, the report’s author … |
|
DowDuPont revealed as the surprise leader in global CRISPR patents; study points to potential trouble ahead
IAM (blog) A new study of the global CRISPR patent landscape released today provides the most detailed insight yet into how entities are seeking to protect their inventions relating to the revolutionary technology. Speaking exclusively to IAM, the report’s author … |
